Pancreatic Cancer Breakthrough: New Daily Pill Nearly Doubles Survival in Major Trial

New drug daraxonrasib from Revolution Medicines doubled survival in pancreatic cancer (13.2 vs 6.7 months) and cut death risk by 60% in Phase 3.